In a phase I/II study, patients with stage IV NSCLC (PD-L1 ≥ 50%) treated with high-dose PDClung01 plus pembrolizumab achieved an impressive ORR of 63.2% and a median PFS of 10.9 months, with acceptable safety [170]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.